EP0643722A4 - N-T-BUTYL-ANDROST-3,5-DIENE-17-g(b)-CARBOXAMIDE-3-CARBOXYLIC ACID POLYMORPH B. - Google Patents
N-T-BUTYL-ANDROST-3,5-DIENE-17-g(b)-CARBOXAMIDE-3-CARBOXYLIC ACID POLYMORPH B.Info
- Publication number
- EP0643722A4 EP0643722A4 EP93908611A EP93908611A EP0643722A4 EP 0643722 A4 EP0643722 A4 EP 0643722A4 EP 93908611 A EP93908611 A EP 93908611A EP 93908611 A EP93908611 A EP 93908611A EP 0643722 A4 EP0643722 A4 EP 0643722A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- polymorph
- androst
- diene
- butyl
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 claims abstract description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000002441 X-ray diffraction Methods 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- XSOKHXFFCGXDJZ-UHFFFAOYSA-N telluride(2-) Chemical compound [Te-2] XSOKHXFFCGXDJZ-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
Definitions
- ACID POLYMORPH B The present invention relates to a novel polymorphic form of N-t-butyl-androst-3,5-diene-17 ⁇ - carboxamide-3-carboxylic acid.
- Figure I is an Infa-red spectrum of N-t-butyl- androst-3,5-diene-17 ⁇ -carboxylic acid polymorph B.
- Figure II is an enhanced FT-IR spectrum of the 3399-3501 cm -1 region of polymorph B disclosing the characteristic N-H stretch of polymorph B.
- N-t-butyl-androst-3,5-diene-17 ⁇ -carboxamide-3- carboxylic acid is a compound which is disclosed and claimed as being useful in the treatment of benign prostatic hypertrophy in U.S. Patent No. 5,017,568, the entire disclosure of which is hereby incorporated by reference.
- Said compound can be prepared by methods such as described in U.S. Patent No. 5,017,568.
- the isolation and identification of the polymorphic forms of said compound is advantageous in identifying desirable physical characteristics of the different crystal forms of said compound.
- polymorph B a polymorphic form of the compound N-t-butyl- androst-3,5-diene-17 ⁇ -carboxamide-3-carboxylic acid can be obtained in a high state of polymorphic purity by crystallization or by precipitation of said compound from or by the trituration of said compound in a solvent consisting of or primarily consisting of acetonitrile, 2-butanone, methanol or tetrahydrofuran.
- contemplated herein is the process of obtaining substantially pure polymorph B by crystallization or by precipitation of said compound from or by the trituration of said compound in a solvent consisting of a combination of solvents selected form acetonitrile, 2- butanone, methanol and tetrahydrofuran.
- a solvent consisting of a combination of solvents selected form acetonitrile, 2- butanone, methanol and tetrahydrofuran.
- a solvent consisting of a combination of solvents selected form acetonitrile, 2- butanone, methanol and tetrahydrofuran.
- a solvent consisting of a combination of solvents selected form acetonitrile, 2- butanone, methanol and tetrahydrofuran.
- crude N-t-butyl-androst-3,5-diene-17 ⁇ -carboxamide-3- carboxylic acid is dissolved in and substantially pure polymorph B is crystalized from a solution of boiling acet
- a 12-40% by weight slurry of N- t-butyl-androst-3,5-diene-17 ⁇ -carboxamide-3-carboxylic acid in acetonitrile is stirred at above ambient temperature.
- a 14-20% by weight slurry of N- t-butyl-androst-3,5-diene-17 ⁇ -carboxamide-3-carboxylic acid in boiling acetonitrile is stirred, preferably for about an hour.
- crude N-t-butyl-androst-3,5- diene-17 ⁇ -carboxamide-3-carboxylic acid is dissolved in and substantially pure polymorph B is precipitated from 2-butanone by concentration and with the addition of petroleum ether.
- N-t-butyl-androst-3,5-diene-17 ⁇ - carboxamide-3-carboxylic acid is known to assume only two polymorphic forms, A and B.
- Table 1 displays the results of equilibrium solubility studies carried out on the two polymorphic forms of N-t-butyl-androst-3,5-diene-17 ⁇ -carboxamide-3- carboxylic acid. The studies were carried out at ambient temperature and the concentration of N-t-butyl- androst-3,5-diene-17 ⁇ -carboxamide-3-carboxylic acid in each solution was measured by ultra violet spectroscopy,
- the polymorph B form is more soluble and has a faster rate of dissolution in water than the polymorph A form.
- Such enhanced solubility properties are advantageous in the preparation of pharmaceutical formulations of N-t-butyl- androst-3,5-diene-17 ⁇ -carboxamide-3-carboxylic acid, such as creams or ointments, and indicates increased Ln vivo bioavailability of said compound.
- N-t-butyl-androst-3, 5-diene-17 ⁇ - carboxamide-3-carboxylic acid is meant a compound of the structure
- N-t-butyl-androst-3, 5-diene-17 ⁇ -carboxamide-3- carboxylic acid polymorph B (prepared by crystallization from acetonitrile) was analyzed by an X-ray powder diffraction (X-ray diffractometry (XRD) obtained from Micron Incorporated of Wilmington, Delaware) .
- XRD X-ray diffractometry
- the characteristic d-spacings, intensities, and 2-theta values for the diffraction pattern of Polymorph B are listed in Table 2 below.
- Acid Polymorph B 33 g of crude N-t-butyl-androst-3,5-diene-17 ⁇ - carboxamide-3-carboxylic acid was added to 150 ml of acetonitrile. The resulting slurry was heated to reflux and stirred for about two hours. The product was isolated by filtration and afforded 27.2 g of substantially pure N-t-butyl-androst-3,5-diene-17 ⁇ - carboxamide-3-carboxylic acid as its B polymorph. The infa-red spectrum of the product is shown in figures one and two.
- An FT-IR spectra of polymorph B is shown in figure 1 below.
- the resolution enhanced FT-IR spectra of the 3399-3501 cm _ l region disclosing said characteristic N-H stretch of polymorph B is shown in Figure 2 below.
- N-t-butv]-androst-3,5-diene-17 ⁇ -carboxamid -3-r.arboxylic. acid Polymorph B Substantially pure N-t-butyl-androst-3,5-diene-17 ⁇ - carboxamide-3-carboxylic acid Polymorph B was obtained by precipitating approximately 10 g of crude N-t-butyl- androst-3,5-diene-17 ⁇ -carboxamide-3-carboxylic acid, from 100 mL of 2-butanone by concentrating the solution under vacuum to about 20 mL and then treating the solution with 163 mL of petroleum ether. The product was collected by filtration, and was dried under vacuum at about 50°C to afford 6.4 g of substantially pure N-t- butyl-androst-3,5-diene-17 ⁇ -carboxamide-3-carboxylic acid Polymorph B.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
Polymorph "B" is a novel polymorphic form of N-t-butyl-androst-3,5-diene-17 beta -carboxamide-3-carboxylic acid. Novel processes for preparing polymorph "B" are also disclosed.
Description
N-T-BUTYL-ANDROST-3.5-DIENE-17β-CARBOXAMIDE-3-CARBOXYLTC
ACID POLYMORPH B The present invention relates to a novel polymorphic form of N-t-butyl-androst-3,5-diene-17β- carboxamide-3-carboxylic acid.
Brief Description of the Drawings
Figure I is an Infa-red spectrum of N-t-butyl- androst-3,5-diene-17β-carboxylic acid polymorph B.
Figure II is an enhanced FT-IR spectrum of the 3399-3501 cm-1 region of polymorph B disclosing the characteristic N-H stretch of polymorph B.
Detailed Description of the Invention N-t-butyl-androst-3,5-diene-17β-carboxamide-3- carboxylic acid is a compound which is disclosed and claimed as being useful in the treatment of benign prostatic hypertrophy in U.S. Patent No. 5,017,568, the entire disclosure of which is hereby incorporated by reference. Said compound can be prepared by methods such as described in U.S. Patent No. 5,017,568. The isolation and identification of the polymorphic forms of said compound is advantageous in identifying desirable
physical characteristics of the different crystal forms of said compound.
It has now been found that a polymorphic form (hereinafter polymorph B) of the compound N-t-butyl- androst-3,5-diene-17β-carboxamide-3-carboxylic acid can be obtained in a high state of polymorphic purity by crystallization or by precipitation of said compound from or by the trituration of said compound in a solvent consisting of or primarily consisting of acetonitrile, 2-butanone, methanol or tetrahydrofuran. Also, contemplated herein is the process of obtaining substantially pure polymorph B by crystallization or by precipitation of said compound from or by the trituration of said compound in a solvent consisting of a combination of solvents selected form acetonitrile, 2- butanone, methanol and tetrahydrofuran. Preferably, crude N-t-butyl-androst-3,5-diene-17β-carboxamide-3- carboxylic acid is dissolved in and substantially pure polymorph B is crystalized from a solution of boiling acetonitrile, said solution optionally containing a co- solvent, preferably methylene chloride, to aid dissolution. Preferably a 12-40% by weight slurry of N- t-butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid in acetonitrile is stirred at above ambient temperature. Preferably a 14-20% by weight slurry of N- t-butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid in boiling acetonitrile is stirred, preferably for about an hour. Preferably, crude N-t-butyl-androst-3,5- diene-17β-carboxamide-3-carboxylic acid is dissolved in and substantially pure polymorph B is precipitated from 2-butanone by concentration and with the addition of petroleum ether.
Presently, N-t-butyl-androst-3,5-diene-17β- carboxamide-3-carboxylic acid is known to assume only two polymorphic forms, A and B.
Table 1 displays the results of equilibrium solubility studies carried out on the two polymorphic forms of N-t-butyl-androst-3,5-diene-17β-carboxamide-3- carboxylic acid. The studies were carried out at ambient temperature and the concentration of N-t-butyl- androst-3,5-diene-17β-carboxamide-3-carboxylic acid in each solution was measured by ultra violet spectroscopy,
Table 1
* 0.1 N Na2HP04, pH 7.5
** ND = Not detected, limit of detection was 0.001 mg/ml
As indicated in Table 1 above, the polymorph B form is more soluble and has a faster rate of dissolution in water than the polymorph A form. Such enhanced solubility properties are advantageous in the preparation of pharmaceutical formulations of N-t-butyl- androst-3,5-diene-17β-carboxamide-3-carboxylic acid, such as creams or ointments, and indicates increased Ln vivo bioavailability of said compound.
- A -
By the term "crude" as used herein is meant that the isolated N-t-butyl-androst-3, 5-diene-17β- carboxamide-3-carboxylic acid starting material exist as an amorphous solid, in an undesired polymorphic form or as a plurality of polymorphic forms .
By the term "N-t-butyl-androst-3, 5-diene-17β- carboxamide-3-carboxylic acid" as used herein is meant a compound of the structure
N-t-butyl-androst-3, 5-diene-17β-carboxamide-3- carboxylic acid polymorph B (prepared by crystallization from acetonitrile) was analyzed by an X-ray powder diffraction (X-ray diffractometry (XRD) obtained from Micron Incorporated of Wilmington, Delaware) . The characteristic d-spacings, intensities, and 2-theta values for the diffraction pattern of Polymorph B are listed in Table 2 below.
Table 2
X-ray diffraction pattern listing of N-t-butyl- androst-3,5-diene-17β-carboxamide-3-carboxylic acid polymorph B.
- 5 -
The following examples illustrate the preparation of N-t-butyl-androst-3,5-diene-17β-carboxamide-3- carboxylic acid polymorph B. The examples are not intended to limit the scope of the invention as defined hereinabove or as claimed below.
- 6 - Example 1
N-t-butyl-androst-3,5-dienβ-17β-carboxamJd -3-carboxylir. acid Polymorph B 33 g of crude N-t-butyl-androst-3,5-diene-17β- carboxamide-3-carboxylic acid was added to 150 ml of acetonitrile. The resulting slurry was heated to reflux and stirred for about two hours. The product was isolated by filtration and afforded 27.2 g of substantially pure N-t-butyl-androst-3,5-diene-17β- carboxamide-3-carboxylic acid as its B polymorph. The infa-red spectrum of the product is shown in figures one and two.
Infra-red spectral absorbancies of N-t-butyl- androst-3,5-diene-17β-carboxamide-3-carboxylic acid polymorph B (prepared by crystallization from acetonitrile) were obtained (spectrm obtained from Nujol (mineral oil) on sodium chloride plates) (Apparatus; Nicolet 6000 FT-IR using a mercury Cadmiun Telluride Detector, analysis time 7.6 minutes (800 scans), Enhancement Program Nicolet IRDCON) .
Characteristic Polymorph B form bands occur at 3455, 3446 cm"1 (N-H stretch); and 1670 cm-1 (acid and amide C=0 stretch) . An FT-IR spectra of polymorph B is shown in figure 1 below. The resolution enhanced FT-IR spectra of the 3399-3501 cm_l region disclosing said characteristic N-H stretch of polymorph B is shown in Figure 2 below.
Example 2
N-t-butyl-androst-3,5-diene-17β-carboxamide-3-carobyxlic
Acid Polymorph B Crude N-t-butyl-androst-3,5-diene-17β-carboxamide- 3-carboxylic acid (10 grams) was dissolved in methylene chloride (250 L) . The reaction solution was distilled at atmospheric pressure to about 85 mL and about 50 mL of acetonitrile was added. The mixture was again
distilled until the head temperature reached 78°C, and the resulting suspension was then heated at reflux for about 1 hour. The slurry was chilled in an ice bath for about 1 hour. The product was isolated by filtration, washed thoroughly with cold acetonitrile, and dried under vacuum at 50-60°C to afford 9.7 grams of N-t- butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid as polymorph B.
Example 3
N-t-butv]-androst-3,5-diene-17β-carboxamid -3-r.arboxylic. acid Polymorph B Substantially pure N-t-butyl-androst-3,5-diene-17β- carboxamide-3-carboxylic acid Polymorph B was obtained by precipitating approximately 10 g of crude N-t-butyl- androst-3,5-diene-17β-carboxamide-3-carboxylic acid, from 100 mL of 2-butanone by concentrating the solution under vacuum to about 20 mL and then treating the solution with 163 mL of petroleum ether. The product was collected by filtration, and was dried under vacuum at about 50°C to afford 6.4 g of substantially pure N-t- butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid Polymorph B.
Claims
What is claimed is:
1. A compound of the structure
substantially in polymorph B form.
2. A compound according to Claim 1 having the infa-red spectrum as shown in Figure 1 and the x-ray diffraction pattern listing shown in Table 2.
3. A compound according to claim 1 having the infa-red spectrum as shown in Figure 2 and the x-ray diffraction pattern listing shown in Table 2.
4. A process for preparing a compound of the structure
substantially in the polymorph B form, which process comprises triturating or crystallizing or precipitating crude N-t-butyl-androst-3, 5-diene-17β-carboxamide-3- carboxylic acid from a solution consisting of or primarily consisting of acetonitrile, 2-butanone, methanol or tetrahydrofuran with subsequent isolation of said polymorph.
5. A process according to claim 4 which comprises triturating crude N-t-butyl-androst-3, 5-diene-17β- carboxamide-3-carboxylic acid in a solution of boiling acetonitrile with subsequent isolation of said polymorph.
6. A process according to claim 4 which comprises precipitating crude N-t-butyl-androst-3, 5-diene-17β- carboxamide-3-carboxylic acid from 2-butanone by concentration and with the addition of petroleum ether with subsequent isolation of 'said polymorph.
7. A process for preparation of a compound of the structure
substantially in the polymorph B form, which comprises triturating or crystallizing or precipitating crude N-t- butyl-androst-3, 5-diene-17β-carboxamide-3-carboxylic acid from a solvent consisting of a combination of solvents selected from acetonitrile, 2-butanone, methanol and tetrahydrofuran with subsequent isolation of said polymorph.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929206414A GB9206414D0 (en) | 1992-03-24 | 1992-03-24 | N-t-butyl-androst-3,5-diene-17b-carboxamide-3-carboxylic acid polymorph b |
| GB9206414 | 1992-03-24 | ||
| PCT/US1993/002862 WO1993019080A1 (en) | 1992-03-24 | 1993-03-24 | N-T-BUTYL-ANDROST-3,5-DIENE-17β-CARBOXAMIDE-3-CARBOXYLIC ACID POLYMORPH B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0643722A1 EP0643722A1 (en) | 1995-03-22 |
| EP0643722A4 true EP0643722A4 (en) | 1995-05-17 |
Family
ID=10712750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP93908611A Ceased EP0643722A4 (en) | 1992-03-24 | 1993-03-24 | N-T-BUTYL-ANDROST-3,5-DIENE-17-g(b)-CARBOXAMIDE-3-CARBOXYLIC ACID POLYMORPH B. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0643722A4 (en) |
| JP (1) | JPH07505369A (en) |
| AU (1) | AU3937393A (en) |
| GB (1) | GB9206414D0 (en) |
| WO (1) | WO1993019080A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0289327A2 (en) * | 1987-04-29 | 1988-11-02 | Smithkline Beecham Corporation | Steroid 5-alpha-reductase inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162543A (en) * | 1990-02-16 | 1992-11-10 | E. R. Squibb & Sons, Inc. | Selective processes for fosinopril polymorphs |
-
1992
- 1992-03-24 GB GB929206414A patent/GB9206414D0/en active Pending
-
1993
- 1993-03-24 EP EP93908611A patent/EP0643722A4/en not_active Ceased
- 1993-03-24 WO PCT/US1993/002862 patent/WO1993019080A1/en not_active Ceased
- 1993-03-24 AU AU39373/93A patent/AU3937393A/en not_active Abandoned
- 1993-03-24 JP JP5516851A patent/JPH07505369A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0289327A2 (en) * | 1987-04-29 | 1988-11-02 | Smithkline Beecham Corporation | Steroid 5-alpha-reductase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO9319080A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0643722A1 (en) | 1995-03-22 |
| JPH07505369A (en) | 1995-06-15 |
| WO1993019080A1 (en) | 1993-09-30 |
| GB9206414D0 (en) | 1992-05-06 |
| AU3937393A (en) | 1993-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9090647B2 (en) | Crystalline forms of rebaudioside B | |
| NO339927B1 (en) | Morphine derivative crystals and process for their preparation | |
| US20040242556A1 (en) | Novel crystalline form of cefdinir | |
| US8063214B2 (en) | Polymorphic forms of tadalafil | |
| EP1133459B1 (en) | Sertraline hydrochloride form v | |
| KR20250003750A (en) | Polymorphs of [2-(1H-Indol-3-yl)-1H-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone and its salts | |
| EP0643722A1 (en) | N-T-BUTYL-ANDROST-3,5-DIENE-17$g(b)-CARBOXAMIDE-3-CARBOXYLIC ACID POLYMORPH B | |
| NO319773B1 (en) | Process for preparing zofenopril calcium salt | |
| NO149635B (en) | PROCEDURE FOR THE PREPARATION OF 1, N- (OMEGA-AMINO-ALFA-HYDROXYALKANOYL) -CANAMYCINE A OR B | |
| HRP930618A2 (en) | Process for the preparation of pure oxytetracycline | |
| GB2183667A (en) | Synthesis of naphthalimide derivatives | |
| EP0633892B1 (en) | N-T-BUTYL-ANDROST-3,5-DIENE-17-beta-CARBOXAMIDE-3-CARBOXYLIC ACID POLYMORPH A | |
| US5596109A (en) | N-t-butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid polymorph A | |
| US5859266A (en) | "N-T-butyl-androst-3-5-diene-17 β-carboxamide-3-carboxylic" acid polymorph A | |
| EP1730153B1 (en) | Isopropanol water solvate of olanzapine | |
| US7393964B2 (en) | Process for the preparation of norelgestromin | |
| RU2521595C2 (en) | Crystalline form ii of tilorone and method of obtaining thereof (versions) | |
| US7501515B2 (en) | Polymorphic form of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-1-en-3-one | |
| CN121517343A (en) | L-proline heterocyclic intermediate, α-methyl-L-proline hydrochloride and its preparation method | |
| CA2558817A1 (en) | Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one | |
| EP1634865A1 (en) | Sertraline hydrochloride polymorphs | |
| EP1790653A2 (en) | Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it | |
| FR2942226A1 (en) | New polymorphic form, crystalline dimethyl sulfoxide solvate and crystalline 1,4-dioxane hemisolvate of 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta(c)chromen-3-yl sulfamate, are steroid sulfatase inhibitors, useful e.g. to treat cancer | |
| JPH03271262A (en) | Production of 4-fluoro-3-nitroanilines | |
| HU193761B (en) | Industrial process for recovering raw vinblastin-sulfate from vinca rosea l |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19941005 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| A4 | Supplementary search report drawn up and despatched | ||
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 19980625 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| RTI1 | Title (correction) |
Free format text: N-T-BUTYL-ANDROST-3,5-DIENE-17-BETA-CARBOXAMIDE-3-CARBOXYLIC ACID POLYMORPH B |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 19991213 |